Ipzz-137 - ((install))

– Beyond oncology, MYC plays a role in certain viral infections (e.g., Epstein‑Barr virus latency) and metabolic diseases (e.g., hepatic steatosis). Proof‑of‑concept studies are evaluating IPZZ‑137 in EBV‑positive post‑transplant lymphoproliferative disorder (PTLD) models.

| | Underlying Issue | Proposed Mitigation | |---------------|----------------------|--------------------------| | Off‑Target Toxicity | Although selectivity screens are favorable, unanticipated binding to other bHLH proteins could affect normal tissue homeostasis. | Conduct comprehensive chemoproteomics (CETSA, DARTS) and in‑vivo safety pharmacology across cardiac, CNS, and hepatic panels. | | Resistance Development | Tumor cells may acquire mutations in the MAX interface or up‑regulate MYC paralogs (e.g., MYCL). | Combine IPZZ‑137 with agents targeting parallel pathways (BET inhibitors, CDK9 inhibitors) and monitor resistance mutations via liquid biopsy. | | Pharmacokinetic Variability | Inter‑patient differences in CYP3A4 activity could alter exposure. | Use therapeutic drug monitoring (TDM) and dose‑adjust based on plasma concentrations; consider a prodrug formulation to bypass first‑pass metabolism. | | Delivery to CNS | MYC‑driven medulloblastoma and glioma are attractive targets but require blood–brain barrier (BBB) penetration. | Optimize a CNS‑penetrant analog (IPZZ‑137‑B) with higher lipophilicity and assess via microdialysis. | | Regulatory Hurdles | Novel PPI inhibitors have limited precedent for approval pathways. | Engage early with FDA’s Oncology Center of Excellence (OCE) for a “breakthrough therapy” designation and leverage the accelerated approval framework using surrogate biomarker endpoints. | ipzz-137

When users encounter issues, providing the exact model or version (like "ipzz-137") can significantly streamline the support process. Support teams can quickly access information specific to that model or version, offering more accurate and timely assistance. – Beyond oncology, MYC plays a role in

In murine sub‑cutaneous xenografts of Daudi lymphoma, oral IPZZ‑137 (30 mg/kg once daily) achieved tumor growth inhibition (TGI) of 92 % after 21 days, with complete regression in 3 of 8 mice. Pharmacodynamic (PD) biomarkers—decreased Ki‑67 staining and reduced MYC‑MAX co‑immunoprecipitation—correlated with drug exposure. No significant weight loss or hematologic toxicity was observed. thereby preventing dimer formation.

Biophysical studies (isothermal titration calorimetry, surface plasmon resonance) revealed that IPZZ‑137 binds directly to the basic helix‑loop‑helix leucine zipper (bHLH‑LZ) domain of MAX with a K_D of 45 nM. By occupying a shallow “hot‑spot” pocket centered on residues Asp‑100 and Trp‑108, the molecule sterically hinders MYC’s ability to engage MAX, thereby preventing dimer formation.